Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Angiotensin-(1-7) Cardiovascular Effects in Aging

Authors not listed

Milton S. Hershey Medical Center · 2022

Abstract

Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-16 MST

Cite this

APA
Anonymous. (2022). Angiotensin-(1-7) Cardiovascular Effects in Aging. <em>Milton S. Hershey Medical Center</em>. https://clinicaltrials.gov/study/NCT05301192
Vancouver
Anonymous. Angiotensin-(1-7) Cardiovascular Effects in Aging. Milton S. Hershey Medical Center. 2022.
BibTeX
@misc{anon2022Angiot, title = {Angiotensin-(1-7) Cardiovascular Effects in Aging}, author = {Anonymous}, journal = {Milton S. Hershey Medical Center}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings